Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 16/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.43 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486059 | 0.86 | TGFBR1 (0.49) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL4490527 | 0.85 | TGFBR1 (0.52) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL4488865 | 0.84 | TGFBR1 (0.47) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL4490850 | 0.84 | MAPK14 (0.47) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL4487787 | 0.83 | TGFBR1 (0.47) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL4481948 | 0.83 | TGFBR1 (0.50) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL4482646 | 0.83 | TGFBR1 (0.52) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL4483524 | 0.82 | TGFBR1 (0.49) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL6757465 | 0.82 | TGFBR1 (0.74) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL6076066 | 0.82 | TGFBR1 (0.47) | TGFBR1MTORMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153872-B2 | Imidazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2006-12-26 | — | — | US | claimed |
| US-7635702-B2 | Imidazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7153872-B2 | Imidazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2006-12-26 | — | — | US | disclosed |
| US-20040106608-A1 | Novel imidazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106608-A1 | Novel imidazole compounds as transforming growth factor (TGF) inhibitors | SMAD3, TGFBR1, TGFBR2 | TGFBR1 2/4885MTOR 81/4885MAPK14 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.